These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26215605)

  • 21. [Management of sunitinib-associated adverse events].
    Kanda H; Masui S; Yamada Y; Arima K; Sugimura Y
    Hinyokika Kiyo; 2012 Nov; 58(11):639-46. PubMed ID: 23254793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study.
    Goebell PJ; Müller L; Hurtz HJ; Koska M; Busies S; Marschner N
    Clin Genitourin Cancer; 2016 Feb; 14(1):63-8. PubMed ID: 26520429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
    De Giorgi U; Rihawi K; Aieta M; Lo Re G; Sava T; Masini C; Baldazzi V; De Vincenzo F; Camerini A; Fornarini G; Burattini L; Rosti G; Moscetti L; Chiuri VE; Luzi Fedeli S; Ferrari V; Scarpi E; Amadori D; Basso U
    J Geriatr Oncol; 2014 Apr; 5(2):156-63. PubMed ID: 24495699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
    Marschner N; Müller L; Münch A; Blumenstengel K; Hutzschenreuter U; Busies S
    J Oncol Pharm Pract; 2017 Jun; 23(4):288-295. PubMed ID: 26908232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
    J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatigue with sunitinib-induced hypothyroidism.
    Senior K
    Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
    [No Abstract]   [Full Text] [Related]  

  • 29. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R
    Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.
    Ibrahim EM; Kazkaz GA; Abouelkhair KM; Bayer AM; Elmasri OA
    Int J Clin Oncol; 2013 Dec; 18(6):1060-9. PubMed ID: 23179639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
    Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
    Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
    Cella D; Davis MP; Négrier S; Figlin RA; Michaelson MD; Bushmakin AG; Cappelleri JC; Sandin R; Korytowsky B; Charbonneau C; Matczak E; Motzer RJ
    Cancer; 2014 Jun; 120(12):1871-80. PubMed ID: 24634003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.
    Pilanc KN; Elbüken F; Ordu Ç; Köksal G; Tekelioğlu MH; Okutur K; Göksel S; Köksal Ü; Akçal T; Tecimer C
    Am J Ther; 2016; 23(2):e583-7. PubMed ID: 24901901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
    Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
    Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.